Citations

Showing 10 of 108081 citations.

Quality of Life in Patients with Vestibular Schwannomas Following Gross Total or Less than Gross Total Microsurgical Resection: Should We be Taking the Entire Tumor Out?
Link, Michael J. , Lund‐Johansen, Morten , Lohse, Christine M. , Driscoll, Colin L. W., Myrseth, Ehrling, Tveiten, Øystein Vesterli , Carlson, Matthew L.

Mayo Clinic

Neurosurgery | April 11, 2017 | Volume: 82 | Issue: 4 | Pages: 541-547

10.1093/neuros/nyx245 | PMID 29554375 Get It

Abstract BACKGROUND The goal of microsurgical removal of a vestibular schwannoma is to completely remove the tumor, to provide long-term durable cure. In many cases, less than gross total resection (GTR) is performed to preserve neurological, and especially facial nerve function. OBJECTIVE To analyze long-term quality of life (QoL) in a cohort of patients who received either GTR or less than GTR. METHODS Patients operated for vestibular schwannoma less than 3.0 cm in posterior fossa diameter at 1 of 2 international tertiary care centers were surveyed using generic and disease-specific QoL instruments. RESULTS A total of 143 patients were analyzed. GTR was performed in 122, and 21 underwent less than GTR. QoL was assessed at a mean of 7.7 yr after surgery (interquartile range: 5.7-9.6). Patients who underwent GTR had smaller tumors; otherwise, there were no baseline differences between groups. Patients who underwent GTR, after multivariable adjustment for baseline features and facial nerve and hearing outcomes, reported statistically significantly better Short Form Health Survey-36 (SF-36) physical and mental scores, Patient-Reported Outcomes Measurement Information System (PROMIS-10) physical and mental scores, and Penn Acoustic Neuroma Quality of Life (PANQOL) facial, energy, general health, and total scores compared to patients receiving less than GTR. CONCLUSION GTR is associated with better QoL using the general QoL measures SF-36 and PROMIS-10 and the disease-specific PANQOL, even after controlling for baseline and outcome differences. This is especially significant in the assessment of mental health, indicating there may indeed be a psychological advantage to the patient that translates to overall well-being to have the entire tumor removed if microsurgical resection is undertaken.
Association Between Midlife Vascular Risk Factors and Estimated Brain Amyloid Deposition
Gottesman, Rebecca F. , Schneider, Andrea L.C. , Gupta, Naresh , Mintz, Akiva , Rahmim, Arman , Sharrett, A. Richey , Wagenknecht, Lynne E. , Wong, Dean F. , Zhou, Yun , Coresh, Josef , Green, Edward , Knopman, David S. , Mosley, Thomas H. , Gottesman, Rebecca F , Schneider, Andrea L C

Mayo Clinic

JAMA | April 11, 2017 | Volume: 317 | Issue: 14 | Pages: 1443

10.1001/jama.2017.3090 | PMID 28399252 Get It

Brain‐responsive neurostimulation in patients with medically intractable mesial temporal lobe epilepsy
Geller, Eric B., Skarpaas, Tara L. , Barkley, Gregory L., Bazil, Carl W., Berg, Michael J. van den, Bergey, Gregory K. , Cash, Sydney S. , Cole, Andrew J. , Duckrow, Robert B., Eisenschenk, Stephan, Fessler, James, Fountain, Nathan B. , Goldman, Alicia, Gwinn, Ryder P. , Heck, Christianne, Herekar, Aamar, Hirsch, Lawrence J. , Jobst, Barbara C. , King‐Stephens, David , Labar, Douglas, Leiphart, James W., Marsh, W. Richard , Meador, Kimford J. , Mizrahi, Eli M., Murro, Anthony M., Nair, Dileep , Park, Yong D., Rutecki, Paul , Salanova, Vicenta , Sheth, Raj D. , Shields, Donald C. , Skidmore, Christopher , Spencer, David , Srinivasan, Shraddha, Tatum, William O. , Ness, Paul C. Van, Vossler, David G. , Wharen, Robert E. , Yoshor, Daniel , Zimmerman, Richard S. , Cicora, Kathy, Sun, Felice T., Morrell, Martha J. , Cole, Andrew J , Noe, Katherine H. , Gross, Robert E. , Goodman, Robert , Berg, Michael J., Edwards, Jonathan , Smith, Michael C. F. , Worrell, Gregory A. , Fountain, Nathan , Hirsch, Lawrence J , Meador, Kimford J , Jobst, Barbara , Nair, Dileep R , Skidmore, Christopher , Morrell, Martha J

Mayo Clinic

Epilepsia | April 11, 2017 | Volume: 58 | Issue: 6 | Pages: 994-1004

10.1111/epi.13740 | PMID 28398014 Get It

SummaryObjectiveEvaluate the seizure‐reduction response and safety of mesial temporal lobe (MTL) brain‐responsive stimulation in adults with medically intractable partial‐onset seizures of mesial temporal lobe origin.MethodsSubjects with mesial temporal lobe epilepsy (MTLE) were identified from prospective clinical trials of a brain‐responsive neurostimulator (RNS System, NeuroPace). The seizure reduction over years 2–6 postimplantation was calculated by assessing the seizure frequency compared to a preimplantation baseline. Safety was assessed based on reported adverse events.ResultsThere were 111 subjects with MTLE; 72% of subjects had bilateral MTL onsets and 28% had unilateral onsets. Subjects had one to four leads placed; only two leads could be connected to the device. Seventy‐six subjects had depth leads only, 29 had both depth and strip leads, and 6 had only strip leads. The mean follow‐up was 6.1 ± (standard deviation) 2.2 years. The median percent seizure reduction was 70% (last observation carried forward). Twenty‐nine percent of subjects experienced at least one seizure‐free period of 6 months or longer, and 15% experienced at least one seizure‐free period of 1 year or longer. There was no difference in seizure reduction in subjects with and without mesial temporal sclerosis (MTS), bilateral MTL onsets, prior resection, prior intracranial monitoring, and prior vagus nerve stimulation. In addition, seizure reduction was not dependent on the location of depth leads relative to the hippocampus. The most frequent serious device‐related adverse event was soft tissue implant‐site infection (overall rate, including events categorized as device‐related, uncertain, or not device‐related: 0.03 per implant year, which is not greater than with other neurostimulation devices).SignificanceBrain‐responsive stimulation represents a safe and effective treatment option for patients with medically intractable epilepsy, including patients with unilateral or bilateral MTLE who are not candidates for temporal lobectomy or who have failed a prior MTL resection.
Lymphoma classification update: B-cell non-Hodgkin lymphomas
Jiang, Manli, Feldman, Andrew L. , Bennani, N. Nora , Feldman, Andrew L

Mayo Clinic

Expert Review of Hematology | April 11, 2017 | Volume: 10 | Issue: 5 | Pages: 405-415

10.1080/17474086.2017.1318053 | PMID 28395545 Get It

Percutaneous Pericardial Resection
Borlaug, Barry A. , Carter, Rickey E. , Melenovský, Vojtěch , Gaba, Prakriti , Killu, Ammar M. , Naksuk, Niyada , Lerman, Lilach O. , Asirvatham, Samuel J. , Killu, Ammar, Lerman, Lilach, DeSimone, Christopher V. , Asirvatham, Samuel J , Borlaug, Barry A , Carter, Rickey E , Melenovský, Vojtěch

Mayo Clinic

Circulation: Heart Failure | April 11, 2017 | Volume: 10 | Issue: 4 | Pages: No page available

10.1161/circheartfailure.116.003612 | PMID 28396500 Get It

Background— People with heart failure and preserved ejection fraction develop increases in left ventricular (LV) end-diastolic pressures during exercise that contribute to dyspnea. In normal open-chest animal preparations, the pericardium restrains LV filling when central blood volume increases. We hypothesized that resection of the pericardium using a minimally invasive epicardial approach would mitigate the increase in LV end-diastolic pressure that develops during volume loading in normal and diseased hearts with the chest intact. Methods and Results— Invasive hemodynamic assessment was performed at baseline and after saline load before and after pericardial resection in normal canines with open (n=3) and closed chest (n=5) and in a pig model with features of human heart failure and preserved ejection fraction with sternum intact (n=4). In closed-chest animals, pericardiotomy was performed using a novel subxiphoid procedure. In both experimental preparations of normal dogs, pericardiotomy blunted the increase in LV end-diastolic pressure with saline infusion, while enhancing the saline-mediated increase in LV end-diastolic volume. With chest intact in the pig model, percutaneous pericardial resection again blunted the increase in LV end-diastolic pressure secondary to volume expansion (+4±3 versus +13±5 mm Hg; P =0.014), while enhancing the saline-mediated increase in LV end-diastolic volume (+17±1 versus +10±2 mL; P =0.016). Conclusions— This proof of concept study demonstrates that pericardial resection through a minimally invasive percutaneous approach mitigates the elevation in LV filling pressures with volume loading in both normal animals and a pig model with diastolic dysfunction. Further study is warranted to determine whether this method is safe and produces similar acute and chronic hemodynamic benefits in people with heart failure and preserved ejection fraction.
A comparison of the diagnostic accuracy of magnetic resonance imaging to axillary ultrasound in the detection of axillary nodal metastases in newly diagnosed breast cancer
Assing, Matthew A., Patel, Bhavika , Karamsadkar, Neel, Weinfurtner, Jared, Kiluk, John V. , Drukteinis, Jennifer S. , Usmani, Omar S. , Patel, Bhavika K

Mayo Clinic

The Breast Journal | April 10, 2017 | Volume: 23 | Issue: 6 | Pages: 647-655

10.1111/tbj.12812 | PMID 28397344 Get It

Adjunctive Corticosteroid Therapy in the Treatment of Coccidioidal Meningitis
Blair, Janis E. , Wang, Sharon, Bercovitch, Robert, Bolaris, Michael , Akker, Dane Van Den, Heidari, Arash , Catanzaro, Antonino , Chin‐Hong, Peter , Spellberg, Brad , Johnson, Royce H. , Thompson, George R , López, Rodrigo , Cadena, José

Mayo Clinic

Clinical Infectious Diseases | April 10, 2017 | Volume: 65 | Issue: 2 | Pages: 338-341

10.1093/cid/cix318 | PMID 28419259 Get It

Neovascularization Failure of an Interposed Free Intestinal Colon Flap 10 Years after Esophageal Reconstruction
Manrique, Oscar J. , Ciudad, Pedro , Chen, Shih‐Heng , Chen, Hung‐Chi

Mayo Clinic

Journal of Reconstructive Microsurgery Open | April 10, 2017 | Volume: 02 | Issue: 01 | Pages: e35-e36

10.1055/s-0037-1601850 Get It

Bioactivity of Oral Linaclotide in Human Colorectum for Cancer Chemoprevention
Weinberg, David S. , Lin, Jieru E. , Foster, Nathan R. , Della’Zanna, Gary , Seisler, Drew K., Katz, Leo C., Waldman, Scott A. , Seisler, Drew, Limburg, Paul J. , Umar, Asad , Kraft, Walter K. , Kastenberg, David , Waldman, Scott A

Mayo Clinic

Cancer Prevention Research | April 10, 2017 | Volume: 10 | Issue: 6 | Pages: 345-354

10.1158/1940-6207.capr-16-0286 | PMID 28396341 Get It

Abstract Guanylate cyclase C (GUCY2C) is a tumor-suppressing receptor silenced by loss of expression of its luminocrine hormones guanylin and uroguanylin early in colorectal carcinogenesis. This observation suggests oral replacement with a GUCY2C agonist may be an effective targeted chemoprevention agent. Linaclotide is an FDA-approved oral GUCY2C agonist formulated for gastric release, inducing fluid secretion into the small bowel to treat chronic idiopathic constipation. The ability of oral linaclotide to induce a pharmacodynamic response in epithelial cells of the colorectum in humans remains undefined. Here, we demonstrate that administration of 0.87 mg of oral linaclotide daily for 7 days to healthy volunteers, after oral colon preparation with polyethylene glycol solution (MoviPrep), activates GUCY2C, resulting in accumulation of its product cyclic (c)GMP in epithelial cells of the cecum, transverse colon, and distal rectum. GUCY2C activation by oral linaclotide was associated with homeostatic signaling, including phosphorylation of vasodilator-stimulated phosphoprotein and inhibition of proliferation quantified by reduced Ki67-positive epithelial cells. In the absence of the complete oral colonoscopy preparation, linaclotide did not alter cGMP production in epithelial cells of the colorectum, demonstrating that there was an effect related to the laxative preparation. These data show that the current FDA-approved formulation of oral linaclotide developed for small-bowel delivery to treat chronic idiopathic constipation is inadequate for reliably regulating GUCY2C in the colorectum to prevent tumorigenesis. The study results highlight the importance of developing a novel GUCY2C agonist formulated for release and activity targeted to the large intestine for colorectal cancer prevention. Cancer Prev Res; 10(6); 345–54. ©2017 AACR.
Clinical Features of Acquired Resistance to Anti–PD-1 Therapy in Advanced Melanoma
Eroglu, Zeynep , Özgün, Alpaslan, Leger, Paul, Ye, Fei , Luke, Jason J. , Haq, Rizwan , Ott, Patrick A. , Hodi, F. Stephen , Sosman, Jeffrey A. , Johnson, Douglas B. , Buchbinder, Elizabeth I. , Wang, Daniel Y. , Zhao, Shilin , Joseph, Richard W. , Luke, Jason J

Mayo Clinic

Cancer Immunology Research | April 10, 2017 | Volume: 5 | Issue: 5 | Pages: 357-362

10.1158/2326-6066.cir-16-0287 | PMID 28396509 Get It

Abstract Anti–PD-1 therapy has improved clinical outcomes in advanced melanoma, but most patients experience intrinsic resistance. Responding patients can develop acquired resistance to anti–PD-1. We retrospectively reviewed 488 patients treated with anti–PD-1 from three academic centers and identified 36 patients with acquired resistance, defined as disease progression following objective response. The incidence, timing, disease sites, post-progression survival (PPS), and outcomes were evaluated descriptively. The acquired resistance cohort consisted of 67% with more than 1 feature of poor prognosis (stage M1c, elevated LDH, or brain metastasis), and 67% had previously received ipilimumab. Partial and complete responses were achieved in 89% (n = 32) and 11% (n = 4) of patients, respectively, and median time to resistance (progression-free survival; PFS) was 11.1 months (range 4.3–32.8 months). Most progression was isolated (78% of patients, n = 28) and occurred while receiving therapy (78%, n = 28). The median PPS was 12.8 months (range 0.1–51.8 months), and the median overall survival was 33.7 months. Among isolated progressors, 15 received localized therapy (12 with surgery, 3 with radiation). Patients with isolated versus systemic progression exhibited a trend for improved PPS (P = 0.081), and patients with an initial PFS ≥ 15 months showed significant PPS improvement (P = 0.036). Two patients experienced subsequent responses to anti–PD-1 resumption. In conclusion, acquired resistance to anti–PD-1 was frequently associated with excellent clinical outcomes and often presented as isolated progression amenable to localized therapy (surgery or radiation) or systemic progression sensitive to therapy resumption. Cancer Immunol Res; 5(5); 357–62. ©2017 AACR.